🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with figures suggesting in excess of 82 million new cases per year. Especially elevated rates are observed in Africa and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Approval

One new antibiotic, also known as Nuzolvence, was approved by the US FDA in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, was also approved in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This approval represents a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Results and Global Access

According to results detailed in a major medical journal, zoliflodacin successfully treated over nine in ten of cases of the STI. This establishes an similar efficacy with the current standard treatment, which uses a dual-drug approach. The research involved over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians directly involved have shared hope. Access to a one-pill regimen like this is seen as a "critical tool" for gonorrhoea control. This is deemed crucial to reduce the burden of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.